Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 14Terminated 6Unknown 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

pembrolizumab 439Carboplatin 322Nivolumab 298Cyclophosphamide 286Specimen Handling 271Magnetic Resonance Spectroscopy 259Cisplatin 250Paclitaxel 249Radiotherapy 230Dexamethasone 184Biopsy 182Gemcitabine 180durvalumab 171atezolizumab 152Doxorubicin 141Rituximab 138Lenalidomide 136Ipilimumab 134Docetaxel 132Bevacizumab 132Radiation 121Capecitabine 120Oxaliplatin 116Etoposide 116Radiosurgery 113Fluorouracil 112Pemetrexed 109fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Depsipeptides × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡